Short Communication: Nucleoside Reverse Transcriptase Inhibitors with Reduced Predicted Activity Do Not Impair Second-Line Therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir-Reference-Cited by-同舟云学术

Short Communication: Nucleoside Reverse Transcriptase Inhibitors with Reduced Predicted Activity Do Not Impair Second-Line Therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir

Published:2018-06 Issue:6 Volume:34 Page:477-480
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Villabona-Arenas Christian Julian¹²,Eymard-Duvernay Sabrina¹,Aghokeng Avelin¹³,Guichet Emilande¹,Toure-Kane Coumba⁴,Bado Guillaume⁵,Koulla-Shiro Sinata⁶,Delaporte Eric¹,Ciaffi Laura¹,Peeters Martine¹

Affiliation:

1. Unité mixte Internationale Recherches Translationnelles sur le VIH et les Maladies Infectieuses (TransVIH-MI, UMI 233 IRD/U1175 Inserm), Institut de Recherche pour le Développement (IRD), Université de Montpellier, Montpellier, France.

2. Laboratoire d'Informatique, de Robotique et de Microélectronique de Montpellier (LIRMM), Institut de Biologie Computationnelle (IBC), Université de Montpellier, Montpellier, France.

3. Centre de Recherche sur les Maladies Emergentes er Réemergentes (CREMER), IMPM-IRD, Yaoundé, Cameroon.

4. Laboratoire de Virologie, Université Cheikh Anta Diop, Dakar, Senegal.

5. Day Care Unit, Hôpital Souro Sanou, Bobo-Dioulasso, Burkina-Faso.

6. Faculté de Médecine et des Sciences Biomédicales, Université de Yaoundé, Yaoundé, Cameroon.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/aid.2017.0290

Reference11 articles.

1. WHO. Clinical guidelines: Antiretroviral therapy. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva, Switzerland: World Health Organization, 2016, p. 480.

2. HIV drug resistance in Africa

3. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study

4. Second line protease inhibitor (PI/r) based antiretroviral therapy (ART) after non-nucleoside reverse transcriptase inhibitor (NNRTI) failure: impact of nucleoside (NRTI) backbone

5. Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV;New England Journal of Medicine;2021-07-22

2. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa;AIDS;2020-04-01

3. Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation;HIV Medicine;2020-01-11

4. An apparent paradox: resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy;Journal of Antimicrobial Chemotherapy;2019-07-12